Mill Capital Management LLC Invests $464,000 in Zimmer Biomet Holdings, Inc. $ZBH

Mill Capital Management LLC purchased a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 5,384 shares of the medical equipment provider’s stock, valued at approximately $464,000.

A number of other large investors have also recently modified their holdings of ZBH. DV Equities LLC purchased a new position in Zimmer Biomet during the 4th quarter worth $25,000. Monetary Solutions Ltd purchased a new stake in shares of Zimmer Biomet in the 4th quarter worth $30,000. Gen Wealth Partners Inc purchased a new stake in shares of Zimmer Biomet in the 4th quarter worth $31,000. Elevation Wealth Partners LLC grew its position in shares of Zimmer Biomet by 145.9% during the 2nd quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 229 shares in the last quarter. Finally, Cornerstone Financial Management LLC bought a new position in shares of Zimmer Biomet during the 4th quarter worth $37,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 1.0%

ZBH stock opened at $100.52 on Friday. The firm has a 50 day moving average of $91.51 and a 200 day moving average of $90.54. The stock has a market capitalization of $19.17 billion, a PE ratio of 24.46, a price-to-earnings-growth ratio of 3.17 and a beta of 0.45. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a 52 week low of $79.12 and a 52 week high of $108.29.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The company had revenue of $2.18 billion for the quarter, compared to the consensus estimate of $2.13 billion. During the same quarter in the previous year, the firm earned $2.07 EPS. Zimmer Biomet’s revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.53 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, July 31st. Stockholders of record on Thursday, June 25th were issued a dividend of $0.24 per share. The ex-dividend date of this dividend was Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s payout ratio is 23.36%.

Wall Street Analysts Forecast Growth

ZBH has been the topic of several research reports. Weiss Ratings upgraded Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, August 4th. UBS Group reiterated a “buy” rating and set a $120.00 target price on shares of Zimmer Biomet in a report on Thursday, August 6th. Zacks Research downgraded shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research report on Monday, July 27th. Citizens Jmp reduced their price target on shares of Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating for the company in a report on Wednesday, April 29th. Finally, BMO Capital Markets reaffirmed a “market perform” rating and issued a $96.00 price target on shares of Zimmer Biomet in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $104.42.

Insider Buying and Selling at Zimmer Biomet

In related news, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the transaction, the insider directly owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This represents a 15.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.28% of the stock is owned by company insiders.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.